Michael Petusky, an analyst from Barrington, maintained the Buy rating on US Physical Therapy. The associated price target remains the same with $103.00.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Michael Petusky has given his Buy rating due to a combination of factors, including U.S. Physical Therapy’s strong financial performance in the third quarter. The company reported total revenue of $197.1 million, surpassing both the firm’s and consensus estimates. This growth was driven by a significant increase in patient revenue and a robust performance in the industrial injury prevention business.
Additionally, the company’s profitability metrics exceeded expectations, with adjusted EPS and EBITDA both coming in higher than anticipated. The solid top-line performance, coupled with effective expense management, contributed to these results. Furthermore, U.S. Physical Therapy reaffirmed its adjusted EBITDA guidance for the fiscal year, indicating confidence in its ongoing financial stability. Petusky maintains an OUTPERFORM rating with a price target of $103, reflecting a 33% upside potential.